Gilead's stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappointsMarket Watch • 01/22/24
Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)Seeking Alpha • 01/08/24
U.S. FDA Approves Label Update for Kite's Yescarta® CAR T-Cell Therapy to Include Overall Survival DataBusiness Wire • 12/21/23
Gilead Sciences and Compugen strike commercialization deal for immunotherapy programProactive Investors • 12/20/23
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy ProgramBusiness Wire • 12/19/23
Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin LymphomasBusiness Wire • 12/12/23